As the Covid-19 pandemic persists, albeit with less-harrowing effects, the South African Health Products Regulatory Authority (Sahpra) has announced its approval of a new oral drug for the treatment of mild to moderate Covid-19 infections, reducing chances of hospitalisation due to the virus.
Last week, Sahpra said it had registered Paxlovid, an anti-viral medicine manufactured by Pfizer, for the treatment of Covid-19.
Paxlovid consists of two separate medications, Nirmatrelvir (150mg) and Ritonavir (100mg), and is used to treat moderate Covid-19 in adults who do not require supplemental oxygen and are at a high risk of severe disease, the drug regulatory body said.
The treatment consists of tablets for a five-day regimen, to be taken morning and evening.
Some of the side-effects include hypersensitivity reactions, diarrhoea, vomiting and altered taste.
Sahpra…